Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by ZITER, F. A.
Right arrow Articles by TYLER, F. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ZITER, F. A.
Right arrow Articles by TYLER, F. H.
NEUROLOGY 1977;27:981
© 1977 American Academy of Neurology

Assessment of muscle strength in Duchenne muscular dystrophy

FRED A. ZITER, M.D., KENT G. ALLSOP, R.P.T., Ph.D and FRANK H. TYLER, M.D.

Division of Pediatric Neurology, Departments of Pediatrics and Neurology, Division of Metabolism, Depattment of Medicine, College of Medicine, and the Department of Physical Therapy, College of Health, University of Utah.

Muscle strength in 23 patients with Duchenne dystrophy was tested against gravity and manual resistance during an 8-year period. The data show striking linearity in rate of loss of strength with age for any given patient. The tempo does not appear altered during growth spurts, bracing, or loss of ambulation. Variability in disease severity was documented clearly by 7 years of age and appears to be related to earlier age at onset of symptoms. This long ignored method of muscle strength assessment provides a precise measure of disease progression and, since the technique is widely used by physical therapists, it should be incorporated in clinical studies and therapeutic trials.

This work was supported in part by grants from the Muscular Dystrophy Association and National Institutes of Health.

Dr. Ziter's address is Division of Pediatric Neurology, Departments of Pediatrics and Neurology, College of Medicine, University of Utah, Salt Lake City, UT 84132.

Accepted for publication February 8, 1977.




This article has been cited by other articles:


Home page
 NeurologyHome page
F. Deymeer, P. Serdaroglu, Y. Parman, and M. Poda
Natural history of SMA IIIb: Muscle strength decreases in a predictable sequence and magnitude
Neurology, August 26, 2008; 71(9): 644 - 649.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
P. J. VIGNOS JR., M. B. WAGNER, B. KARLINCHAK, and B. KATIRJI
Evaluation of a Program for Long-Term Treatment of Duchenne Muscular Dystrophy. Experience at the University Hospitals of Cleveland
J. Bone Joint Surg. Am., December 1, 1996; 78(12): 1844 - 52.
[Abstract] [Full Text]

Home page
 Arch NeurolHome page
J. R. Mendell, M. A. Province, R. T. Moxley III, R. C. Griggs, M. H. Brooke, G. M. Fenichel, J. P. Miller, K. K. Kaiser, W. King, J. Robison, et al.
Clinical Investigation of Duchenne Muscular Dystrophy: A Methodology for Therapeutic Trials Based on Natural History Controls
Arch Neurol, August 1, 1987; 44(8): 808 - 811.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
L. Z. Stern, S. P. Ringel, F. A. Ziter, K. B. Menander-Huber, V. Ionasescu, R. J. Pellegrino, and R. D. Snyder
Drug Trial of Superoxide Dismutase in Duchenne's Muscular Dystrophy
Arch Neurol, June 1, 1982; 39(6): 342 - 346.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
K. G. Allsop and F. A. Ziter
Loss of Strength and Functional Decline in Duchenne's Dystrophy
Arch Neurol, July 1, 1981; 38(7): 406 - 411.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1977 by AAN Enterprises, Inc.